Research Topics
| Samir K BallasSummaryAffiliation: Thomas Jefferson University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Update on pain management in sickle cell diseaseSamir K Ballas
Department of Medicine, Cardeza Foundation, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Hemoglobin 35:520-9. 2011..Cellular and molecular mechanisms of opioids explain individual differences among patients and justify the use of individualized treatment plans...- Defining the phenotypes of sickle cell diseaseSamir K Ballas
Department of Medicine, Cardeza Foundation, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Hemoglobin 35:511-9. 2011..The aim of this review is to define the complications that are specific to sickle cell disease based on available evidence in the literature and the experience of hematologists in this field... 
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on managementSamir K Ballas
Cardeza Foundation and Department of Medicine, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
ScientificWorldJournal 2012:949535. 2012..We hope that this will establish another preliminary forum among providers that may eventually lead the way to better outcomes...
Pain management of sickle cell diseaseSamir K Ballas
Cardeza Foundation for Hematologic Research, Philadelphia, PA 19107, USA
Hematol Oncol Clin North Am 19:785-802, v. 2005..Management of chronic pain should take a multidisciplinary approach...- Management of acute chest wall sickle cell pain with nebulized morphineSamir K Ballas
Cardeza Foundation for Hematologic Research, Philadelphia, Pennsylvania 19107, USA
Am J Hematol 76:190-1. 2004..This is a desirable alternative in patients with difficult venous access and may more specifically target chest pain... - Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndromeSamir K Ballas
Cardeza Foundation, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Hemoglobin 28:85-102. 2004..Children appeared to benefit more than adults. The data and safety profile justify further studies with purified poloxamer 188 in the treatment of ACS... - Folate supplementation and twinning in patients with sickle cell diseaseSamir K Ballas
Department of Medicine, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Am J Hematol 81:296-7. 2006..In this report, we present our experience in patients with sickle cell disease and twin pregnancy. Our data show that twin pregnancies seem to be associated with folate supplementation... - Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemiaSamir K Ballas
Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Transfusion 46:105-10. 2006..These changes have been attributed to, but not proven, hyperhemolysis. This study provides evidence of hyperhemolysis in this group of patients... - Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significanceSamir K Ballas
Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia Pennsylvania, USA
Am J Hematol 79:17-25. 2005..It suggests that improvement is needed in the management of pain during hospitalization and at home after discharge. Patients who are readmitted frequently within 1 week of discharge have poor prognosis and require careful monitoring... - Early detection of response to hydroxyurea therapy in patients with sickle cell anemiaSamir K Ballas
Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Hemoglobin 34:424-9. 2010..These changes were first detected 10 weeks after starting HU and before the increase in Hb F levels. The data suggest that subtle and early markers of response to HU reside in the hemogram... - Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at homeSamir K Ballas
Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
J Pain Symptom Manage 40:870-82. 2010..Recurrent acute painful crises may be mild, moderate, or severe in nature and often require treatment at home, in acute care facilities as outpatients, and in the hospital with oral and/or parenteral opioids... - The impact of hydroxyurea on career and employment of patients with sickle cell anemiaSamir K Ballas
Cardeza Foundation, Department of Medicine, Thomas Jefferson University, 1015 Walnut St, Philadelphia, PA 19107, USA
J Natl Med Assoc 102:993-9. 2010.... - Definitions of the phenotypic manifestations of sickle cell diseaseSamir K Ballas
Department of Medicine, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
Am J Hematol 85:6-13. 2010.... - Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndromeSamir K Ballas
Thomas Jefferson University, Philadelphia, PA 19107, USA
Hemoglobin 30:165-70. 2006..00 AU at any point in time during follow-up. The data indicate that the reliability of sPLA(2( for predicting the development of ACS is not perfect (100%) as was previously reported but occurs in about 80% of the patients... - Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemiaSamir K Ballas
Sickle Cell Center, Cardeza Foundation for Hematologic Research, Jefferson Medical College, 1015 Walnut St, Philadelphia, PA 19107, USA
J Natl Med Assoc 101:1046-51. 2009..The same argument seems to apply for exposure to opioids. However, it will take a much longer follow-up of many more hydroxyurea-exposed sickle cell disease subjects to establish the results conclusively... 
Hydroxyurea and sickle cell anemia: effect on quality of lifeSamir K Ballas
Cardeza Foundation, Department of Medicine, Jefferson Medical College, Philadelphia, PA, USA
Health Qual Life Outcomes 4:59. 2006..The morbidity associated with this disease is known to have serious negative impact on the overall quality of life(QOL) of affected individuals...- Clinically significant differences in the visual analog pain scale in acute vasoocclusive sickle cell crisisBernard L Lopez
Department of Emergency Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
Hemoglobin 31:427-32. 2007..A DeltaVAS <13.5 mm may not be clinically important. This finding may assist the clinician in the assessment of pain improvement for adult sickle cell patients with VOC... - The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-upMartin H Steinberg
Department of Medicine, Boston University School of Medicine, Boston Medical Center, Massachusetts, USA
Am J Hematol 85:403-8. 2010..Our results, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment, suggest that long-term use of hydroxyurea is safe and might decrease mortality... - Non-pharmacologic management of sickle cell painPaul Brown Bodhise
Bodhise Holistic Healing Group, Philadelphia, PA, USA
Hematology 9:235-7. 2004.... - L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency departmentBernard L Lopez
Department of Emergency Medicine, Jefferson Medical College, Philadelphia, PA, USA
Br J Haematol 120:532-4. 2003..16 micromol/l +/- 5.04) and significantly low plasma NOx (12.33 micromol/l +/- 10.28, P < 0.05 vs steady-state control = 25.2 +/- 2.6 micro mol/l). Neither l-arg nor NOx levels could predict VOC clinical course... - Investigational drugs in sickle cell anemiaSandy D Kotiah
Cardeza Foundation, Philadelphia, PA 19107, USA
Expert Opin Investig Drugs 18:1817-28. 2009..In this paper, we review the drugs that are now being investigated in the treatment of sickle cell anemia... - Blood samples collected under venous oxygen pressure from patients with sickle cell disease contain a significant number of a new type of reversibly sickled cells: constancy of the percentage of sickled cells in individual patients during steady stateToshio Asakura
Division of Hematology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
Am J Hematol 80:249-56. 2005..This new type of RSC may be used as an internal biomarker to evaluate the disease state of individual patients... - Sickle red cell microrheology and sickle blood rheologySamir K Ballas
Department of Medicine, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Philadelphia, Pennsylvania, USA
Microcirculation 11:209-25. 2004..The focus of this review is on the rheology of sickle blood and microrheology of sickle RBC. Determinants of sickle RBC rheology and the factors that modulate its severity are discussed... - Sickle cell anaemia: progress in pathogenesis and treatmentSamir K Ballas
Department of Medicine, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Philadelphia, PA 19107, USA
Drugs 62:1143-72. 2002..Curative gene therapy continues to be investigational at the level of the test tube and transgenic mouse models... - Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year studyKenneth Epstein
Department of Medicine, University of Colorado School of Medicine, Denver, CO, USA
J Natl Med Assoc 98:1109-13. 2006..The healthcare utilization of our adult sickle cell population is very complex, with a subset of our patients accounting for a majority of the resources used and female patients living longer but with less ED and hospital admissions... - Drugs for preventing red blood cell dehydration in people with sickle cell diseaseSrikanth Nagalla
Department of Medicine, Division of Hematology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Cochrane Database Syst Rev 7:CD003426. 2012..Recent research has focused on therapies to rehydrate the sickled cells by reducing the loss of water and ions from them. Little is known about the effectiveness and safety of such drugs... - Sickle cell pain: a critical reappraisalSamir K Ballas
Cardeza Foundation, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA
Blood 120:3647-56. 2012..Management of sickle cell pain should be based on its own pathophysiologic mechanisms rather than borrowing guidelines from other nonsickle pain syndromes... - Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion servicesRichard W Toner
Jefferson School of Population Health, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Appl Health Econ Health Policy 9:29-37. 2011..little is known about the economics of acquiring and processing the more than 14 million units of red blood cells used annually in the US... - Bloodstream infections in hospitalized adults with sickle cell disease: a retrospective analysisLalita Chulamokha
Division of Infectious Diseases and Environmental Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Am J Hematol 81:723-8. 2006..Also, if patients are critically ill, consideration should be made to include antifungal agents. Additional research into the adult SCD population appears necessary to further define this problem... - Changes in mu opioid receptors and rheological properties of erythrocytes among opioid abusersAllen R Zeiger
Department of Biochemistry and Molecular Pharmacology, Thomas Jefferson University, Philadelphia, PA, USA
Addict Biol 7:207-17. 2002..This study may offer clues to the biological properties of peripheral blood cells that may be mediated by mu opioid receptors and lead to a better understanding of some of the clinical effects of opioid use... - Meperidine for acute sickle cell pain in the emergency department: revisited controversySamir K Ballas
Ann Emerg Med 51:217. 2008 - Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell diseaseMartin H Steinberg
Boston University School of Medicine, Room 211, 88 E Newton Street, Boston, MA 02118, USA
Am J Hematol 72:121-6. 2003..Our results provide additional evidence that some elements that regulate HbF expression are linked to the beta-globin gene cluster... - Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatmentMartin H Steinberg
Boston University School of Medicine, Center of Excellence in Sickle Cell Disease, Boston Medical Center, Boston, Mass 02118, USA
JAMA 289:1645-51. 2003..Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality... - Urease enhances the formation of iron nitrosyl hemoglobin in the presence of hydroxyureaVirginia L Lockamy
Department of Physics, Wake Forest University, Winston-Salem, NC 27109-7507, USA
Biochim Biophys Acta 1622:109-16. 2003..We show that addition of urease, which converts HU to HA, to a mixture of blood and HU, greatly enhances HbNO formation... - Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell diseaseDeborah Dean
Children s Hospital Oakland Research Institute, 5700 Martin Luther King Jr Way, Oakland, CA 94609, USA
J Pediatr Hematol Oncol 25:46-55. 2003..The purpose of this study was to analyze the clinical course and outcome of C. pneumoniae-associated ACS among SCD patients as part of the National Acute Chest Syndrome Study... - Hydroxyurea analogues as kinetic and mechanistic probes of the nitric oxide producing reactions of hydroxyurea and oxyhemoglobinJinming Huang
Departments of Chemistry and Physics, Wake Forest University, Winston-Salem, NC 27109, USA
J Med Chem 46:3748-53. 2003..These results should guide the development of new hydroxyurea-based nitric oxide donors and sickle cell disease therapies... - Kinetics of increased deformability of deoxygenated sickle cells upon oxygenationZhi Huang
Departments of Physics and Chemistry, Wake Forest University, Winston-Salem, North Carolina 27109 USA
Biophys J 85:2374-83. 2003..These data imply that persistence of sickle cell hemoglobin polymers during circulation in vivo is likely, due to slow and incomplete polymer melting, contributing to the pathophysiology of sickle cell disease... - Treatment of painful sickle cell leg ulcers with topical opioidsSamir K Ballas
Blood 99:1096. 2002 - N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell diseaseRoberto F Machado
Vascular Medicine Branch, Clinical Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1454, USA
JAMA 296:310-8. 2006..Levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) provide such information in patients with idiopathic pulmonary arterial hypertension... - Effects of iron nitrosylation on sickle cell hemoglobin solubilityXiuli Xu
Department of Physics, Wake Forest University, Winston-Salem, North Carolina 27109, USA
J Biol Chem 277:36787-92. 2002..Given the small amounts of NO-ligated hemoglobin achievable through any kind of NO therapy, we conclude that NO therapy does not benefit patients through any direct solubilizing effect... - Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overloadEllen B Fung
Department of Hematology, Children s Hospital and Research Center, Oakland, California, USA
Am J Hematol 82:255-65. 2007..Long term follow-up of this unique cohort of subjects will be helpful in further defining the relationship of chronic, heavy iron overload to morbidity and mortality... - Iron nitrosyl hemoglobin formation from the reactions of hemoglobin and hydroxyureaJinming Huang
Department of Chemistry, Wake Forest University, Winston-Salem, North Carolina 27109, USA
Biochemistry 41:2466-74. 2002..These direct nitric oxide producing reactions of hydroxyurea and hemoglobin may contribute to the overall pathophysiological properties of this drug...